The Role of Inflammation in AMD and Related Disorders

Study Overview
=================
Brief Summary
-----------------
This prospective, non-therapeutic study will compare the relative utility of multiple ocular imaging modalities in the detection of the cellular immune response in patients with AMD and related disorders.

Official Title
-----------------
In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) & Related Conditions

Conditions
-----------------
Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Procedure: multi-modal cSLO imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria STUDY EYE Any tentative clinical diagnosis of the following: Early dry AMD (drusen) with clinical suspicion of CNV Late dry AMD (GA) with clinical suspicion of CNV Reticular Pseudodrusen with clinical suspicion of CNV Polypoidal choroidal vasculopathy Retinal Angiomatous Proliferation Central Serous Retinopathy RPE detachment Conversion to wet AMD (CNV) Decade matched controls Inclusion Criteria CONTROL EYE Subjects > 18 years of age Best corrected visual acuity (BCVA) of 20/32 or better Exclusion Criteria STUDY/CONTROL EYE: Patients not able to provide consent for the study. Patients with a poor view of the fundus due to cataract or vitreous hemorrhage. Patients < 18 years of age Patients with known allergy to angiographic dye Patients with any concurrent unrelated eye diagnosis that would interfere with image acquisition or interpretation (eg advanced diabetic retinopathy, vascular occlusion, uveitis, or others). Exclusion Criteria CONTROL EYE Suspect diagnosis of AMD, RPD, PCV, RAP, CSR or RPED Family history of AMD 2 or more large drusen (>125um) or 20 or more medium drusen (64-124um) Diabetes Patients using Plaquenil/Chloroquine/Hydroxychloroquine Diagnosis of inflammatory disease Patients with inherited eye disease Note: patients with a diagnosis of nevi are NOT excluded from this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early dry AMD (no GA)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Late dry AMD (with GA)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Reticular Pseudodrusen (RPD)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Polypoidal Choroidal Vasculopathy (PCV)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Retinal Angiomatous Proliferaion (RAP)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Central Serous Retinopathy (CSR)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| RPE Detachment (RPED)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| New onset CNVM (wet AMD)<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |
| Healthy (non-AMD) controls<br>multi-modal cSLO imaging | Procedure: multi-modal cSLO imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visualization of RPE damage and presumptive immune cells | Qualitative | 8 months |